Campbell Alliance

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Retrieved on: 
火曜日, 5月 7, 2024
University, Cancer, CD47, Campbell Alliance, Investment, GU, Commercial, Hematology, Marketing, Trial of the century, Medulloblastoma, Bevacizumab, Growth, Roche, Consultant, Senior, Science, Patient, Acquisition, Lead, CBO, Howard Hughes Medical Institute, SAN

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).
  • “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology.
  • “For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer.
  • “With near-term clinical trial readouts and a strong balance sheet, ALX Oncology is well positioned for greater success.

Validant Group Announces New Leadership

Retrieved on: 
月曜日, 5月 15, 2023
Professional Services, Medical Supplies, Health, Medical Devices, Consulting, Pharmaceutical, Biotechnology, Validation (drug manufacture), IBM, Campbell Alliance, Medical Affairs Bureau, Partnership, Senior, GHO, IDEC, Health care, Multimedia, Development, Growth, Research, Syneos Health, FDA, Heidrick, OSAM, Heidrick & Struggles, Management, Audit, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230515005123/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230515005123/en/
    Tim Dietlin, Chief Executive Officer (CEO), The Validant Group (Photo: Business Wire)
    “Tim brings a unique skill set to his role as CEO of the Validant Group.
  • Tim Dietlin brings more than 25 years of leadership experience to his role as CEO of the Validant Group.
  • “Together, the Validant Group will deliver a full-service platform that provides unmatched regulatory clarity at every phase of the product life cycle.
  • I look forward to cultivating and continuing to grow a united Validant Group that is stronger together and positioned for success.”
    The Validant Group is a global, full-service life science consulting company focused on managing and resolving complex regulatory issues.

KELIX bio Enters Into a Binding Commitment to Acquire PHI, a Leading Pharmaceutical Manufacturer in Morocco

Retrieved on: 
火曜日, 3月 8, 2022
Biotechnology, Pharmaceutical, Health, Leadership, Population, AMO, European Bank for Reconstruction and Development, ANSM, Medication, CDC Group, PHI, GMP, Emerging market, European Central Bank, Reconstruction, CDC, Campbell Alliance, Fine chemical, Pharmaceutical industry, Public relations, Kingdom, Nadir Sedrati

KELIX bio, a unique pan-African biopharmaceutical platform, today announced it has entered into a binding commitment to acquire Pharmaceutical Institute (PHI), a leading pharmaceutical company established in Rabat.

Key Points: 
  • KELIX bio, a unique pan-African biopharmaceutical platform, today announced it has entered into a binding commitment to acquire Pharmaceutical Institute (PHI), a leading pharmaceutical company established in Rabat.
  • PHI was established in 1989 by the Sedrati family and is a leading manufacturer and distributor of pharmaceutical products in Morocco.
  • We are privileged to have reached an agreement with the founders and look forward to welcoming them to KELIX bio, said Hocine Sidi-Said, Chief Executive Officer at KELIX bio.
  • About KELIX bio: KELIX bio, is a specialty generic business focused on Emerging Markets that seeks to compete through innovation and cost leadership.

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
水曜日, 9月 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
水曜日, 9月 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

Blue Matter Again Ranked as One of the 25 Best Consulting Firms to Work for in Europe; Ranked #1 in 5 Categories

Retrieved on: 
火曜日, 1月 19, 2021
Service companies, Ernst & Young, Consulting, Consulting firm, Consultant, Companies, Campbell Alliance

LONDON, Jan. 19, 2021 /PRNewswire/ -- For the second year running, Blue Matter has earned a ranking as one of the 25 best consulting firms to work for in Europe.

Key Points: 
  • LONDON, Jan. 19, 2021 /PRNewswire/ -- For the second year running, Blue Matter has earned a ranking as one of the 25 best consulting firms to work for in Europe.
  • The firm was ranked 11th overall on the Vault Consulting 25 List (Europe) for 2021.
  • In addition, Blue Matter earned the top spot in five of the survey categories.
  • From its offices in North America and Europe, Blue Matter serves pharmaceutical and biotech companies from around the globe.

The Planet Group Announces Agreement to Acquire NDA Partners, a Life Sciences Management Consulting and Contract Development Organization

Retrieved on: 
水曜日, 11月 4, 2020
Medical devices, Finance, Consulting, Banking, Accounting, Professional services, Biotechnology, Health, Pharmaceutical, Articles, Business, Contract research organizations, Economy, Advisors, Consultant, Small business, Management consulting, Clinical research, Campbell Alliance

The Planet Group ("Planet"), a leading provider of outsourced human capital and consulting solutions and a portfolio company of MidOcean Partners, announced today that it has entered into an agreement to acquire NDA Partners, a global life sciences management consulting and contract development organization focused on providing innovative product development and regulatory services to the pharmaceutical, biotechnology and medical device industries.

Key Points: 
  • The Planet Group ("Planet"), a leading provider of outsourced human capital and consulting solutions and a portfolio company of MidOcean Partners, announced today that it has entered into an agreement to acquire NDA Partners, a global life sciences management consulting and contract development organization focused on providing innovative product development and regulatory services to the pharmaceutical, biotechnology and medical device industries.
  • This is a really exciting deal for Planet as we continue to follow our expansion strategy, said Michael Stomberg, CEO of The Planet Group.
  • NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology and medical device industries worldwide.
  • Services include efficient product development and regulatory strategy, expert consulting, high-impact project teams and contract management of client product development programs.

Coeus Consulting Group Partners with Harrison Consulting Group to Expand Its Capabilities and Client Offerings

Retrieved on: 
火曜日, 3月 12, 2019
Health, Biotechnology, Small business, Medical devices, Pharmaceutical, Professional services, Consulting, Other Science, Science, Business, Articles, Economy, Management consulting, Advisors, Consultant, Small business, Campbell Alliance

Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has entered in to a strategic partnership with the Harrison Consulting Group.

Key Points: 
  • Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has entered in to a strategic partnership with the Harrison Consulting Group.
  • Prior to founding the Harrison Consulting Group, William Bill Ashton was a former Fortune 100 senior executive with over 35 years experience in the biotechnology and pharmaceutical business.
  • Harrison Consulting Group was founded by industry expert William Ashton in 2006 to assist pharmaceutical clients to optimize their commercial launch success.
  • Founded in 2009, Coeus Consulting Group is a boutique life science strategy consulting firm supporting pharmaceutical, biotech, medical device, and payors in the U.S.